Daily Stock Analysis, AFMD, Affimed NV, priceseries

Affimed NV. Daily Stock Analysis
Stock Information
Open
2.10
Close
2.00
High
2.10
Low
2.00
Previous Close
2.15
Daily Price Gain
-0.15
YTD High
2.35
YTD High Date
Jan 10, 2017
YTD Low
1.65
YTD Low Date
Jan 20, 2017
YTD Price Change
-0.10
YTD Gain
-4.76%
52 Week High
5.00
52 Week High Date
Apr 25, 2016
52 Week Low
1.65
52 Week Low Date
Jan 20, 2017
52 Week Price Change
-1.25
52 Week Gain
-38.46%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 20. 2015
7.74
Apr 28. 2015
8.73
6 Trading Days
12.86%
Link
LONG
May 19. 2015
8.21
Jun 11. 2015
11.31
16 Trading Days
37.76%
Link
LONG
Jun 30. 2015
13.47
Jul 20. 2015
16.65
13 Trading Days
23.62%
Link
LONG
Nov 23. 2015
6.21
Dec 3. 2015
6.77
7 Trading Days
8.99%
Link
LONG
Mar 1. 2016
3.68
Mar 9. 2016
3.87
6 Trading Days
5.10%
Link
Company Information
Stock Symbol
AFMD
Exchange
NasdaqGM
Company URL
http://www.affimed.com
Company Phone
49-6221-65307
CEO
Adi Hoess
Headquarters
-
Business Address
IM NEUENHEIMER FELD 582, 69120, HEIDELBERG, GERMANY 000000
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001608390
About

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell mal...

Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company's product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Its AFM21 product also binds CD3, directing T-cells to destroy tumor cells that carry EGFRvIII. Affimed N.V. has license agreements with Amphivena Therapeutics, Inc. and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and clinical research collaboration with Merck & Co Inc. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.